These cancer/neoplasm- and immunity/inflammation-related processes showed the up- and downregulation of genes that were altered in Tsc2+/− and TscD+/− mice (Additional file 2: Fig. S2B), respectively, indicating that the severity of symptoms that are related to cancer/neoplasm and immunity/inflammation would be different between TSC patients with underlying TSC1 and TSC2 mutations. This evidence concerns the gene TSC1 and neoplasm.